Quick Answer: Retatrutide has no current US price because it isnt FDA approved as of May 2026 Tirzepatide pen prices when introduced: Mounjaro (T2D label): ,069.08 per month list Zepbound (obesity label): ,059.87 per month list Lilly priced both tirzepatide formulations to undercut Wegovy (semaglutide 2.4 mg at ,349 list) by about 20 percent
It's called "off-label" use when a drug is prescribed for something outside of the FDA's recommendation
Adv Nutr 8(3):511519 [DOI] [PMC free article] [PubMed] [Google Scholar] 38.Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB et al (2024) Incretin-Based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition
Neurodegeneration 15 , 8 (2020)
The genetic layer beneath any tirzepatide decision Because tirzepatide engages incretin biology, your own metabolic genetics shape the terrain it acts on